See the media release below on leadXpro AG and InterAx Biotech AG, joining forces to discover and optimize new drug lead molecules targeting G-protein coupled receptors.
Record revenues of CHF 7.3 billion (USD 8.1 billion) – Capital investments increase by more than 50% to CHF 2 billion – CHF 1.4 billion by public companies, CHF 0.6 billion by private companies – Significant licensing and M&A activity in 2023 – VectivBio, T3, Vertex, Santhera – R&D investments of publicly traded biotech companies have decreased in line with global markets, wherea
AllesHealth, a renowned provider of comprehensive healthcare solutions for clinics and patients, announces a strategic partnership with Biorce, a leading innovator in AI for drug development. This collaboration is set to transform the landscape of clinical trials by integrating Biorce’s cutting-edge AI technology with AllesHealth’s advanced Clinic & Patient Management solutions
Hevolution Foundation and Dolby Family Ventures join ND Capital as additional institutional investors bringing Series A funding to a total of $30.7M (CHF28.3M) Vandria’s lead CNS compound VNA-318 is a mitophagy inducer about to enter clinical development with a unique dual mode of action of immediate improvement of cognitive function paired with long-term disease-modifying effects Series A runwa
LeadXpro achieved a world-first milestone in partnership with Cumulus Oncology: solving high-resolution agonist and antagonist protein structures of GPR68, in their drug discovery project for therapeutic intervention in oncology and inflammation.
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that its SOPHiA DDM Platform is now CE marked under the European Union’s In Vitro Diagnostic Regulation (IVDR).
Valneva obtains exclusive worldwide license for LimmaTech’s S4V Shigella vaccine candidate and adds an attractive Phase 2 clinical asset to Valneva’s R&D pipeline LimmaTech to receive upfront payment, is eligible for future milestone and royalty payments, and will collaborate on S4V clinical development through Phase 2